Popular GLP-1 Weight Loss Drugs Linked to Risk of Sudden Vision Loss
Summary
New research shows that popular diabetes and weight loss drugs called GLP-1 receptor agonists may slightly raise the risk of a rare eye problem called ischemic optic neuropathy (ION), which can cause sudden vision loss. Although the risk is small, patients should watch for sudden changes in vision and get medical help right away if symptoms appear.Key Facts
- GLP-1 drugs include semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound).
- The study found a small increase in ION risk for Type 2 diabetes patients starting GLP-1 drugs compared to other diabetes medicines.
- ION happens when blood flow to the optic nerve is reduced, possibly causing sudden, painless vision loss.
- The increase in risk was about three to four extra cases per 10,000 patients over 18 months.
- Researchers used U.S. insurance data from adults aged 18 to 65 between 2017-2022.
- Experts advise patients not to stop GLP-1 medications but to immediately report any sudden vision changes.
- The study found an association but did not prove GLP-1 drugs cause ION.
- GLP-1 drugs are known for benefits in diabetes, obesity, heart, and kidney health.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
